REPCF (0913693 BC) Shares Outstanding (EOP): 65.00 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is 0913693 BC Shares Outstanding (EOP)?

0913693 BC REPCF Shares Outstanding (EOP) is 65.00 Mil as of Sep. 2023.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. 0913693 BC's shares outstanding for the quarter that ended in Sep. 2023 was 65.00 Mil.

0913693 BC's quarterly shares outstanding stayed the same from Jun. 2023 (65.00 Mil) to Sep. 2023 (65.00 Mil).

0913693 BC's annual shares outstanding increased from Dec. 2021 (34.96 Mil) to Dec. 2022 (47.60 Mil). It means 0913693 BC issued new shares from Dec. 2021 to Dec. 2022 .


0913693 BC  (OTCPK:REPCF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


0913693 BC Shares Outstanding (EOP) Related Terms


0913693 BC Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for 0913693 BC's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

0913693 BC Shares Outstanding (EOP) Chart

0913693 BC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.80 28.29 33.52 34.96 47.60

0913693 BC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.75 47.60 65.00 65.00 65.00

REPCF vs VRTX, REGN, SGEN: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, 0913693 BC's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


0913693 BC Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 0913693 BC's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where 0913693 BC's Shares Outstanding (EOP) falls into.



0913693 BC Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 65.00 Mil mean?
0913693 BC (REPCF) has a Shares Outstanding (EOP) of 65.00 Mil as of Sep. 2023. The total shares a company has outstanding, at period-end. View historical data on 0913693 BC and its competitors.
Is 0913693 BC's Shares Outstanding (EOP) too high?
0913693 BC's current Shares Outstanding (EOP) is 65.00 Mil.
How does 0913693 BC's Shares Outstanding (EOP) compare to VRTX and REGN?
0913693 BC's Shares Outstanding (EOP) of 65.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on 0913693 BC and its competitors. 0913693 BC's current Shares Outstanding (EOP) is 65.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 0913693 BC stock overvalued right now?
0913693 BC (REPCF) has a current Shares Outstanding (EOP) of 65.00 Mil. The current Shares Outstanding (EOP) is 65.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For 0913693 BC (REPCF), the current Shares Outstanding (EOP) is 65.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

0913693 BC Business Description

Address 570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
0913693 BC Ltd is a regenerative medicine company focused on aesthetics and orthopedics. It is a royalty company that holds its primary royalty assets focused on autologous cell therapies that treat functional cellular deficits, including chronic tendon injuries, androgenetic alopecia, and skin aging. The Company is organized into one business unit based on its cell replication technology and has one reportable operating segment. Its product line is RCT-01 Tendon Repair, RCS-01 Skin Rejuvenation, RCH-01 Hair Growth, and DermaPrecise.